StreetInsider.com News Articles

TD Cowen Reiterates Buy Rating on CVS Health (CVS)

Fri, 13 Mar 2026 09:26:31 -0400

TD Cowen analyst Charles Rhyee reiterated a Buy rating and $105.00 price target on CVS Health (NYSE: CVS).

The analyst commented: "Consumer Pharmacy Survey Shows Positive Results for CVS; We ran a proprietary survey of 2,251 US consumers, asking questions about their retail pharmacy preferences. Data was positive for CVS: it remains the most popular pharmacy, has above-market level of customer loyalty, and should gain share from competitor closures. While main focus NT is on final MA rates, we remind investors PCW is another lever of growth and view segment guide as conservative."

For an analyst ratings summary and ratings history on

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Investing.com -- Bernstein upgraded both Cigna Group and CVS Health Corp to Outperform in separate notes on Thursday, arguing that sweeping pharmacy benefit manager (PBM) reforms have removed a major overhang for the sector.

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

CVS Health Deepens Commitment to Nashville With $120,000 Investment in Cul2vate's "Roots and Roofs" Initiative

Thu, 12 Mar 2026 08:30:00 -0400

Investment strengthens local organizations to advance food access, workforce development, and housing stability in underserved communities.

WOONSOCKET, RI / ACCESS Newswire / March 12, 2026 / Originally published on CVS Health Company News

CVS Health® (NYSE:CVS) in collaboration with Elmington Capital and Cul2vate recently announced a further investment of $120,000 in Cul2vate's Roots and Roofs initiative, a program designed to connect affordable, stable housing with food security and workforce development in Nashville, Tennessee.

This latest commitment builds on CVS Health's initial investment in the development of 101 Factory, an affordable

CVS Health Deepens Commitment to Nashville With $120,000 Investment in Cul2vate's "Roots and Roofs" Initiative

Thu, 12 Mar 2026 08:30:00 -0400

Investment strengthens local organizations to advance food access, workforce development, and housing stability in underserved communities.

WOONSOCKET, RI / ACCESS Newswire / March 12, 2026 / Originally published on CVS Health Company News

This latest commitment builds on CVS Health's initial investment in the development of 101 Factory, an affordable

Bernstein SocGen Group Upgrades CVS Health (CVS) to Outperform

Thu, 12 Mar 2026 07:59:51 -0400

Bernstein SocGen Group analyst Lance Wilkes upgraded CVS Health (NYSE: CVS) from Market Perform to Outperform with a price target of $94.00 (from $91.00).

The analyst commented: "We are upgrading CVS to Outperform and modestly increasing our PT to $94 which presents 23% upside. We see CVS as having attractive exposure to the MA turnaround and potential for more stable earnings in its pharmacy and PBM businesses after PBM reform impacts. We entered 2026 believing that CVS turnaround progress was positive but uncertainty around PBM reform would hold back shares. We see the recent PBM bill passage and the first FTC

Bernstein SocGen Group Upgrades CVS Health (CVS) to Outperform

Thu, 12 Mar 2026 07:59:51 -0400

Bernstein SocGen Group analyst Lance Wilkes upgraded CVS Health (NYSE: CVS) from Market Perform to Outperform with a price target of $94.00 (from $91.00).

CVS Health Foundation Invests $2.24 Million to Expand Community‑Based Care Through Health Impact Ohio